Epilepsy More Common With Frontotemporal Dementia
By Lori Solomon HealthDay Reporter
TUESDAY, June 10, 2025 -- Epilepsy is more common among those with frontotemporal dementia (FTD) than among people with Alzheimer disease (AD) or healthy controls, according to a study published online June 2 in JAMA Neurology.
Annemari Kilpeläinen, M.D., from University of Eastern Finland in Kuopio, and colleagues conducted a case-control study to examine whether epilepsy is more prevalent in patients with FTD (245) than in matched healthy controls (2,416) or patients with AD (1,326). Analysis compared purchases of antiseizure medicines (ASMs).
The researchers found that the prevalence of epilepsy was higher in the FTD group versus controls (3.3 versus 0.8 percent) and the AD group (3.3 versus 1.4 percent) 10 years before FTD diagnosis. At the year of the diagnosis, the prevalence was 6.5 percent for those with FTD, 1.8 percent for controls, and 5.0 percent in patients with AD. Five years following diagnosis, the prevalence was 11.2 percent in patients with FTD, 2.2 percent in controls, and 6.9 percent in patients with AD. At all time points, ASM purchases were made significantly more often among patients with FTD (10.2 percent) versus controls (1.8 percent) or patients with AD (4.2 percent) and increased during the study period.
"Knowledge about the association between epilepsy and FTD raises new research questions: do these diseases share some pathophysiological mechanisms and could some FTD symptoms be caused by alterations in the specific electrical systems of the brain," Eino Solje, also from University of Eastern Finland, said in a statement.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity
TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...
Dementia Risk Does Not Differ With GLP-1 RAs, DPP4is for Seniors With T2DM
MONDAY, July 21, 2025 -- For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using glucagon-like peptide 1...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.